214 related articles for article (PubMed ID: 31161831)
21. Estimating the Economic Impact of Adding Panobinostat to a U.S. Formulary for Relapsed and/or Refractory Multiple Myeloma: A Budget Impact and Cost-Benefit Model.
Bloudek L; Roy A; Kish JK; Siegel DS; Jagannath S; Globe D; Orloski L; Kuriakose ET
J Manag Care Spec Pharm; 2016 Aug; 22(8):991-1002. PubMed ID: 27459662
[TBL] [Abstract][Full Text] [Related]
22. Cost effectiveness of pomalidomide in patients with relapsed and refractory multiple myeloma in Sweden.
Borg S; Nahi H; Hansson M; Lee D; Elvidge J; Persson U
Acta Oncol; 2016 May; 55(5):554-60. PubMed ID: 27123742
[TBL] [Abstract][Full Text] [Related]
23. Ixazomib significantly prolongs progression-free survival in high-risk relapsed/refractory myeloma patients.
Avet-Loiseau H; Bahlis NJ; Chng WJ; Masszi T; Viterbo L; Pour L; Ganly P; Palumbo A; Cavo M; Langer C; Pluta A; Nagler A; Kumar S; Ben-Yehuda D; Rajkumar SV; San-Miguel J; Berg D; Lin J; van de Velde H; Esseltine DL; di Bacco A; Moreau P; Richardson PG
Blood; 2017 Dec; 130(24):2610-2618. PubMed ID: 29054911
[TBL] [Abstract][Full Text] [Related]
24. Cost-effectiveness of Drugs to Treat Relapsed/Refractory Multiple Myeloma in the United States.
Carlson JJ; Guzauskas GF; Chapman RH; Synnott PG; Liu S; Russo ET; Pearson SD; Brouwer ED; Ollendorf DA
J Manag Care Spec Pharm; 2018 Jan; 24(1):29-38. PubMed ID: 29290170
[TBL] [Abstract][Full Text] [Related]
25. Safety and Effectiveness of Ixazomib Dose-escalating Strategy in Ixazomib-Lenalidomide-Dexamethasone Treatment for Relapsed/Refractory Multiple Myeloma.
Ohashi Y; Yatabe M; Niijima D; Tani K; Ogawa C; Yachi Y; Kagoo T; Boku S; Ueno H; Yano T; Higai K; Yokoyama A
In Vivo; 2020; 34(5):2821-2828. PubMed ID: 32871820
[TBL] [Abstract][Full Text] [Related]
26. Cost Effectiveness of Triplet Selinexor-Bortezomib-Dexamethasone (XVd) in Previously Treated Multiple Myeloma (MM) Based on Results from the Phase III BOSTON Trial.
Dolph M; Tremblay G; Leong H
Pharmacoeconomics; 2021 Nov; 39(11):1309-1325. PubMed ID: 34368938
[TBL] [Abstract][Full Text] [Related]
27. Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trial.
Richardson PG; Oriol A; Beksac M; Liberati AM; Galli M; Schjesvold F; Lindsay J; Weisel K; White D; Facon T; San Miguel J; Sunami K; O'Gorman P; Sonneveld P; Robak P; Semochkin S; Schey S; Yu X; Doerr T; Bensmaine A; Biyukov T; Peluso T; Zaki M; Anderson K; Dimopoulos M;
Lancet Oncol; 2019 Jun; 20(6):781-794. PubMed ID: 31097405
[TBL] [Abstract][Full Text] [Related]
28. [Efficacy and Safety of Ixazomib-Lenalidomide-Dexamethasone Therapy for Relapsed and Refractory Multiple Myeloma].
Takakuwa T; Araki T; Miura A; Fujitani Y; Takeoka Y; Ohta K; Yamamura R
Gan To Kagaku Ryoho; 2019 Jun; 46(6):1043-1047. PubMed ID: 31273172
[TBL] [Abstract][Full Text] [Related]
29. Cost Offsets in the Treatment Journeys of Patients With Relapsed/Refractory Multiple Myeloma.
Ailawadhi S; DerSarkissian M; Duh MS; Lafeuille MH; Posner G; Ralston S; Zagadailov E; Ba-Mancini A; Rifkin R
Clin Ther; 2019 Mar; 41(3):477-493.e7. PubMed ID: 30773308
[TBL] [Abstract][Full Text] [Related]
30. Efficacy of ixazomib-lenalidomide-dexamethasone in high-molecular-risk relapsed/refractory multiple myeloma - case series and literature review.
Szudy-Szczyrek A; Chocholska S; Bachanek-Mitura O; Czabak O; Mlak R; Szczyrek M; Muzyka-Kasietczuk J; Hus M
Ann Agric Environ Med; 2022 Mar; 29(1):103-109. PubMed ID: 35352912
[TBL] [Abstract][Full Text] [Related]
31. Management of adverse events associated with ixazomib plus lenalidomide/dexamethasone in relapsed/refractory multiple myeloma.
Kumar S; Moreau P; Hari P; Mateos MV; Ludwig H; Shustik C; Masszi T; Spencer A; Hájek R; Romeril K; Avivi I; Liberati AM; Minnema MC; Einsele H; Lonial S; Berg D; Lin J; Gupta N; Esseltine DL; Richardson PG
Br J Haematol; 2017 Aug; 178(4):571-582. PubMed ID: 28485007
[TBL] [Abstract][Full Text] [Related]
32. Cost-effectiveness of once-weekly selinexor, bortezomib, and dexamethasone in relapsed or refractory multiple myeloma.
Patel KK; Parker T; Di M; Bar N; Huntington SF; Giri S
Leuk Lymphoma; 2021 Nov; 62(11):2777-2784. PubMed ID: 34151696
[TBL] [Abstract][Full Text] [Related]
33. Carfilzomib-Dexamethasone Versus Bortezomib-Dexamethasone in Relapsed or Refractory Multiple Myeloma: Updated Overall Survival, Safety, and Subgroups.
Orlowski RZ; Moreau P; Niesvizky R; Ludwig H; Oriol A; Chng WJ; Goldschmidt H; Yang Z; Kimball AS; Dimopoulos M
Clin Lymphoma Myeloma Leuk; 2019 Aug; 19(8):522-530.e1. PubMed ID: 31160237
[TBL] [Abstract][Full Text] [Related]
34. A real-world retrospective-prospective analysis of efficacy and safety of combined ixazomib, lenalidomide, and dexamethasone in relapsed/refractory multiple myeloma: The northern Italy experience.
Furlan A; Cea M; Pavan L; Galli M; Clissa C; Mangiacavalli S; Cafro AM; Girlanda S; Patriarca F; Minotto C; Bertoldero G; Barilà G; Pascarella A; Lico A; Paolini R; Rabassi N; Pescosta N; Porrazzo M; De Sabbata G; Pompa A; Bega G; Cavallin S; Guidotti F; Marcatti M; Rupolo M; Belotti A; Gherlinzoni F; Zambello R
Cancer Med; 2024 Apr; 13(7):e7071. PubMed ID: 38558233
[TBL] [Abstract][Full Text] [Related]
35. Ixazomib - the first oral proteasome inhibitor.
Xie J; Wan N; Liang Z; Zhang T; Jiang J
Leuk Lymphoma; 2019 Mar; 60(3):610-618. PubMed ID: 30614337
[TBL] [Abstract][Full Text] [Related]
36. Clinical study on ixazomib in the treatment of multiple myeloma.
He Y; Zhang K; Zou L; Chen S; Jiang D; Hu J; Zhu Y
Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2020 Mar; 45(3):322-327. PubMed ID: 32386025
[TBL] [Abstract][Full Text] [Related]
37. Phase I/II trial of bendamustine, ixazomib, and dexamethasone in relapsed/refractory multiple myeloma.
Dhakal B; D'Souza A; Hamadani M; Arce-Lara C; Schroeder K; Chhabra S; Shah NN; Gauger K; Keaton T; Pasquini M; Hari P
Blood Cancer J; 2019 Jul; 9(8):56. PubMed ID: 31358733
[TBL] [Abstract][Full Text] [Related]
38. Cost-effectiveness of Pomalidomide, Carfilzomib, and Daratumumab for the Treatment of Patients with Heavily Pretreated Relapsed-refractory Multiple Myeloma in the United States.
Pelligra CG; Parikh K; Guo S; Chandler C; Mouro J; Abouzaid S; Ailawadhi S
Clin Ther; 2017 Oct; 39(10):1986-2005.e5. PubMed ID: 28967482
[TBL] [Abstract][Full Text] [Related]
39. Ixazomib in the management of relapsed multiple myeloma.
Touzeau C; Moreau P
Future Oncol; 2018 Aug; 14(20):2013-2020. PubMed ID: 29469592
[TBL] [Abstract][Full Text] [Related]
40. [Safety and management of adverse events of ixazomib/lenalidomide/dexamethasone therapy in Japanese patients with relapsed/refractory multiple myeloma].
Iida S; Izumi T; Aotsuka N; Komeno T; Ishida T; Sunami K; Handa H; Berg D; Kase Y; Soeda J
Rinsho Ketsueki; 2018; 59(11):2399-2407. PubMed ID: 30531133
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
